米勒娃科学 NERV 深 沪
已收盘 02-06 16:00:00 美东时间
4.80
+0.580
+13.74%
华盛通- 最 高4.92
- 今 开4.29
- 成交量 7.81万股
- 最 低 4.13
- 昨 收 4.22
- 总市值 2.08亿
- 52周最高 12.46
- 市盈率 静 25.26
- 换手率 0.18%
- 52周最低 1.15
- 委 比 70.39%
- 总股本 4327.44万
- 历史最高 126.72
- 量 比 0.74
- 振 幅 18.72%
- 历史最低 1.15
- 每 手 1
- 风险率 1.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Minerva Neurosciences Unveils Roluperidone Phase 3 Trial Plans for Negative Symptoms of Schizophrenia
Minerva Neurosciences Unveils Roluperidone Phase 3 Trial Plans for Negative Symptoms of Schizophrenia Minerva Neurosciences Inc. has released a presentation outlining developments related to roluperidone, a potential treatment for the negative symptoms of schizophrenia. The presentation details gene
02-04 05:35
Minerva Neurosciences kündigt virtuelle Expertenveranstaltung zu Phase-3-Studie mit Roluperidon an
Minerva Neurosciences kündigt virtuelle Expertenveranstaltung zu Phase-3-Studie mit Roluperidon an Minerva Neurosciences Inc. veranstaltet am Dienstag, den 3. Februar 2026, um 10:30 Uhr Eastern Time eine virtuelle Key Opinion Leader (KOL) Veranstaltung. Dabei werden unter anderem weitere Details zur
02-03 22:01
Minerva Neurosciences to Host Virtual Key Opinion Leader Event
Minerva Neurosciences to Host Virtual Key Opinion Leader Event Minerva Neurosciences Inc. will host a virtual key opinion leader (KOL) event on Tuesday, February 3, 2026, at 10:30 a.m. Eastern Time. During the event, the company will provide additional details about its proposed confirmatory Phase 3
02-03 22:01
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
Minerva Neurosciences将举办一场虚拟KOL会议，探讨精神分裂症阴性症状的负担及评估挑战。会议邀请了专家格雷戈里·施特劳斯博士和布莱恩·柯克帕特里克博士，他们将与公司管理团队讨论其III期临床试验roluperidone如何应对这些挑战。当前抗精神病药物未能有效治疗阴性症状，Minerva计划启动新型研究方案的III期试验，以解决这一未满足的医疗需求。
01-26 12:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock rose 63.6% to $3.19 during W...
2025-12-24 20:05
Minerva Neurosciences Expands Board Amid Fundraising Effort
Minerva Neurosciences ( ($NERV) ) has shared an update. On November 14, 2025, M...
2025-11-19 21:58
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Minerva Neurosciences announced the appointment of Dr. Inderjit Kaul as a board member and consultant for the clinical development of roluperidone to treat negative symptoms of schizophrenia. The company recently raised $200 million to fund a confirmatory Phase 3 trial for roluperidone, aiming to address a significant unmet medical need. Dr. Kaul, with extensive experience in schizophrenia drug development, will support Minerva's efforts to advan...
2025-11-19 13:30
Minerva Neurosciences (NERV) Gets a Hold from H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao maintained a Hold rating on Minerva Neuros...
2025-11-10 09:16
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Minerva Neurosciences GAAP EPS of -$0.36
Minerva Neurosciences press release (NERV): Q3 GAAP EPS of -$0.36. Reported a Q3 net loss of $2.74M. More on Minerva Neurosciences Minerva Neurosciences rises on financing of up to $200M to advance Sc...
2025-11-06 01:34
